Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05904028 · ClinicalTrials.gov registry record · Phase 3

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

A Phase 3 study of Neovascular Age-related Macular Degeneration, sponsored by Jaeb Center for Health Research.

Recruiting
Registry status
Phase 3
Development phase
600
Enrollment target
20
Study locations

NCT05904028: Recruiting Phase 3 study of Neovascular Age-related Macular Degeneration, sponsored by Jaeb Center for Health Research.

NCT05904028 is a Phase 3 study of Neovascular Age-related Macular Degeneration that is actively recruiting participants, run by Jaeb Center for Health Research. The registered enrollment target is 600 participants, above the 390-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (54% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05904028, a Phase 3 study of Neovascular Age-related Macular Degeneration, is actively recruiting participants, sponsored by Jaeb Center for Health Research.

RECRUITING
Registry status
Phase 3
Development phase
600 participants
Enrollment target
20
Study locations

Study Summary

Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.

Primary Outcome

Best-corrected visual acuity following protocol-defined refraction. Visual Acuity measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/10) to 0 letters (Snellen equivalent of \<20/800). Higher scores indicate better visual acuity, and lower scores indicate worse visual acuity.

Conditions Studied

Neovascular Age-related Macular Degeneration

Interventions

  • DRUG Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule
  • DEVICE Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule

Study Locations (20)

Florida

  • National Ophthalmic Research Institute - Fort Myers
  • National Ophthalmic Research Institute - Fort Myers
  • University of Florida- Jacksonville - Jacksonville
  • Florida Retina Institute, James A. Staman, MD, PA- Jacksonville - Jacksonville
  • Argus Research Center, Inc - Naples
  • Southeast Eye Institute, P.A. dba Eye Associates of Pinellas - Pinellas Park
  • Retina Associates of Sarasota - Sarasota
  • Sarasota Retina Institute - Sarasota
  • Retina Associates of Florida, LLC - Tampa

California

  • Kent W. Small, MD, AMC - Glendale
  • Loma Linda University - Loma Linda
  • East Bay Retina Consultants, Inc. - Oakland
  • Kaiser Permanente - Oakland - Oakland
  • Southern California Desert Retina Consultants, Inc. - Palm Desert
  • UC Davis Health Eye Center - Sacramento
  • Macula Retina Vitreous Institute - Torrance
  • Bay Area Retina Associates A Medical Group - Walnut Creek

Georgia

  • Southeast Retina Center, P.C. - Augusta
  • Thomas Eye Group - Sandy Springs

Connecticut

  • Retina Consultants - Manchester

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2023-11-09
Est. Completion 2027-07-30
Phase Phase 3
Jaeb Center for Health Research

119 total trials

What NCT05904028 shows while recruiting

NCT05904028 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 390-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (54% higher).

The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule is the first listed.

NCT05904028 names 20 study sites across 4 states, led by Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT05904028 about?

NCT05904028 is a clinical study titled "Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD". Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.

What is the current status of trial NCT05904028?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2023-11-09. Estimated completion is 2027-07-30.

What conditions does trial NCT05904028 study?

This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.

What interventions are being tested in trial NCT05904028?

The interventions under investigation include: Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule (DRUG), Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule (DEVICE).

Who is sponsoring clinical trial NCT05904028?

This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05904028 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neovascular Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05904028's enrollment target sits among peer trials

600 6th of 33 higher than 28 of 33 other Neovascular Age-related Macular Degeneration trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Neovascular Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05904028

Source: ClinicalTrials.gov NCT05904028, the US trial registry maintained by the National Library of Medicine. NCT05904028 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.